NA Proactive news snapshot: Aequus Pharmaceuticals, American Battery Metals, Orgenesis, EXMceuticals UPDATE ..

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) is welcoming seasoned ophthalmology executive Stu Fowler, who is coming on board as a strategic commercial advisor with a seat on the firm’s board. Fowler recently serves as the general manager of Alcon in Canada and was formerly president of Allergan Canada. Both firms are among the largest ophthalmology companies in the country. The Vancouver-based firm also announced that its chief commercial officer Ian Ball is transitioning into a senior role with the firm’s UK partner Medicom Healthcare. Doug Cole, CEO of American Battery Metals Corporation (OTCMKTS:ABML), the battery recycling and resource production group, is keen to stress that lithium-ion battery recycling offers a way to bolster the environmental soundness of the electric vehicle industry. Under its current program, the Nevada company takes in fully-charged lithium-ion batteries and extracts lithium, cobalt, nickel, copper and aluminum to redeploy them for other uses in batteries. “We see our lithium-ion battery recycling process as both a solution and an opportunity,” said Cole. “We are helping to solve the growing e-waste problem, reduce the carbon footprint of the EV industry – both up and downstream – and we are doing so in a manner that is profitable for our company and cost-effective for the supply chain.” Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, announced Monday that Catalent Pharma Solutions has agreed to acquire one of its subsidiaries in a deal worth $127 million to the company. In a statement, Orgenesis said it expects to use the net proceeds from the sale of subsidiary Masthercell Global Inc, a contract development manufacturing organization (CDMO), to continue to grow its point-of-care cell therapy business and to further the development of Advanced Therapy Medicinal Products. The transaction is expected to close during the current fiscal first quarter of 2020. Masthercell, which is also backed by healthcare-investment firm Great Point Partners and Belgian-government backed investment group SFPI-FPIM, helps companies shorten lead times and lower costs in getting cell therapies and products to the market. EXMceuticals Inc (CSE:EXM) has appointed the former president of Portugal’s health regulator, Dr Eurico Castro Alves, to its advisory board.  The new advisor is also the founder of WiseHS medical and Pharmaceutical consulting, a European business and clinical consultancy that offers guidance to the medical cannabis industry.  Capstone Turbine Corp. (NASDAQ:CPST), the manufacturer of microturbines, is widening its reach in the Caribbean after winning a new order from a rum distillery in Jamaica.  The undisclosed distillery signed a contract with Capstone as it required on-site power and hot water for the production of its rum. This new 200kW project, which is set to be commissioned by March, is comprised of a low-pressure natural gas-fueled Capstone microturbine that provides a low-cost alternative to expensive utility costs in Jamaica. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Monday that it has achieved its patient screening target for an upcoming trial of its Zygel CBD gel as a treatment for Fragile X syndrome. Zynerba plans to move forward with the 14-week trial at clinical sites in the US, Australia and New Zealand, now with more than 200 patients enrolled. Top-line results are expected later this year, and if they’re positive, Zynerba expects to meet with the US Food and Drug Administration to submit a New Drug Application. If all goes according to plan, Zygel could be approved to treat Fragile X by mid-2021. Heritage Cannabis Holdings Corp (CSE:CANN) (OTCMKTS:HERTF) says it is to advance the business with a C$6.7 million loan from Trichome Financial Corp. Trichome already advanced the cannabis group C$4.875 million on January 30. It will provide a further C$1.825 million when the firm receives a Health Canada sales licence or Heritage achieving consolidated revenues of C$7.5 million - whichever comes sooner. XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) has raised C$2 million gross from a fully subscribed private placing to fund its European imports business. In a statement on Monday, the group said it plans to expand its EU lab processing and storage capacity. The funds will also be used for regulatory compliance, inventory purchase and product development, manufacturing, and distribution, as well as for working capital. Imagination Park Technologies Inc. (CNSX:IP.CN) (OTCMKTS:IPNFF) said it has engaged the services of financial portal Stockhouse.com to provide increased market awareness and investor relations services to the company.  Alen Paul Silverrstieen, Imagination Park CEO commented: "As the Only Augmented Reality Platform that can create immersive AR Activations within two minutes anywhere in the world, we are excited to work with the experienced team at Stockhouse.com to increase investor awareness of our AR technology platform and ever-expanding client list in North America which includes the NBA Sacramento Kings”. Royal Road Minerals Limited (CVE:RYR) announced that it has entered into an agreement with Mineros S.A. to amend its previously announced letter of intent (LOI) in relation to the company's Guintar and Niverengo concessions and its Margaritas title application in Antioquia District, Colombia. The agreement extends the deadline for entering into a definitive agreement with Mineros from January 30, 2020 to March 30, 2020. eWellness Healthcare Corporation (OTCMKTS:EWLL), a provider of the state of the art PHZIO platform for the physical therapy (PT) and telehealth markets, announced today that it is developing and will deploy a new MSK360 App during the first quarter of 2020. The firm is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments and its business model is to have large-scale employers use the MSK360 and/or our PHZIO platform as a fully PT monitored corporate MSK (musculoskeletal) corporate wellness program. Genprex Inc (NASDAQ:GNPX) will be presenting at the upcoming Noble Capital Markets 16th Annual Investor Conference, held February 16-18 at the Seminole Hard Rock Hotel & Casino in Hollywood, Florida. CEO Rodney Varner will deliver an overview of the company and provide updates on its product pipeline, including a recently-received Fast Track Designation for its drug Oncoprex. Genprex is scheduled to present at 1:30 pm ET on Monday, February 17 in Terrace Ballroom A. One-on-one meetings with the company can be made by emailing investors@genprex.com.